OTC ranitidine two-tablet effervescent dose subject of ANDA suitability petition.
This article was originally published in The Tan Sheet
Executive Summary
OTC RANITIDINE TWO-TABLET EFFERVESCENT DOSE containing 37.5 mg of the H2 antagonist ingredient per tablet is the subject of a Sept. 3 ANDA suitability petition filed with FDA on behalf of an unnamed company. The two-tablet dose of the acid blocker would differ from a one-tablet 75 mg dose of Warner-Lambert's Zantac 75 in "dosage form and amount of active ingredient per tablet," Thomas Blake, a Budd Lake, N.J.-based regulatory strategist, says in the petition.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning